MK-0608 (MK608; 7-deaza-2'-C-methyladenosine; 7-DMA.) is a novel and potent anti-viral agent against HCV replication with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay.
Physicochemical Properties
| Molecular Formula | C12H16N4O4 |
| Molecular Weight | 280.284 |
| Exact Mass | 280.117 |
| CAS # | 443642-29-3 |
| PubChem CID | 3011893 |
| Appearance | White to off-white solid powder |
| Density | 1.8±0.1 g/cm3 |
| Boiling Point | 620.7±55.0 °C at 760 mmHg |
| Melting Point | 222 °C(Solv: methanol (67-56-1) |
| Flash Point | 329.2±31.5 °C |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.769 |
| LogP | 0.22 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 20 |
| Complexity | 373 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C(N=CN=C32)N)CO)O)O |
| InChi Key | IRZRJANZDIOOIF-GAJNKVMBSA-N |
| InChi Code | InChI=1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1 |
| Chemical Name | (2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol |
| Synonyms | MK-608 MK608 MK 608MK 0608 MK-0608 MK06087-deaza-2'-C-methyladenosine 7-DMA |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | HCV replication(EC50= 0.3 μM) |
| ln Vivo | When MK-0608 is taken orally, it has a strong antiviral effect. MK-0608 shows good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in dogs and rhesus macaques (9 and 14 h, respectively) in preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys[1]. |
| Animal Protocol |
Animal Model: The HCV-infected chimpanzees[1] Dosage: 1 mg/kg Administration: Administered orally; once daily for 37 days Result: Baseline viral loads for chimpanzees X6 and X4 ranged from 1,110 to 12,900 IU/mL and 3×106 to 9×106 IU/mL, respectively. |
| References | [1]. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53(3):926-34. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~891.97 mM） |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (7.42 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5679 mL | 17.8393 mL | 35.6786 mL | |
| 5 mM | 0.7136 mL | 3.5679 mL | 7.1357 mL | |
| 10 mM | 0.3568 mL | 1.7839 mL | 3.5679 mL |